D.C. Circuit Refuses to Freeze Marijuana Rescheduling

The D.C. Circuit refused on September 9 to freeze the April 28 marijuana rescheduling order. The motion for a stay pending review was the one procedural move with the power to pull Schedule III back from state-licensed medical operators before the court reaches the merits, and the court disposed of it in a sentence: petitioners "have not satisfied the stringent requirements for a stay pending court review." Marijuana under state medical licenses and FDA-approved drug products containing marijuana stay in Schedule III while the consolidated challenges proceed.

For anyone buying edibles at a dispensary, nothing changes at the counter. What changes is the cost base underneath it. Licensed medical operators keep 280E tax relief for the life of the litigation, which is months at minimum, while the hemp channel loses federal status in two steps: November 12 for cannabinoids the plant cannot make, December 11 for everything else. One channel got its legal footing confirmed and its tax bill cut. The other got a shutdown date. The consolidation thesis just tightened.

Who asked the court to freeze rescheduling?

Two petitioners filed the June 9 stay motion: the National Drug and Alcohol Screening Association, a drug-testing trade group, and MMJ International Holdings, a pharmaceutical company pursuing cannabinoid drugs through FDA. Both described their interests in their own filing. NDASA's medical review officers earn most of their revenue from marijuana-positive results. MMJ has spent eight years on the FDA pathway.

The motion is unusually candid about the money. It tells the court that marijuana-positive results are the largest source of revenue for the medical review officers in NDASA's membership and projects a revenue decline of at least 35 percent within a year. The drug-testing industry asked a federal appeals court to keep marijuana in Schedule I so that employers would keep paying to test for it.

MMJ's case is stranger. The company says it has spent over $10 million and eight years developing cannabinoid therapeutics exclusively through FDA and DEA channels, and that letting state-licensed medical marijuana into Schedule III erodes the "market opportunities" that discipline was supposed to earn. The Department of Justice put it less gently in its July 2 response, describing both petitioners as invoking "pocketbook interests served by keeping all marijuana in schedule I."

What did the D.C. Circuit actually decide?

The court denied a stay, and nothing more. It did not rule on the merits question, which is whether the Attorney General can reschedule marijuana by order under section 811(d) of the Controlled Substances Act without formal rulemaking. The April order stays in effect. The parties have 30 days to propose a briefing format, so a merits decision is months out at the earliest.

The case is three consolidated petitions: Smart Approaches to Marijuana on May 4, Nebraska and Indiana on May 22 (Louisiana signed on and withdrew a week later), and a coalition including MMJ, treatment providers, and physicians on May 28. NDASA and MMJ moved for the stay June 9, DOJ responded July 2, and the denial came September 9. The same order denied intervention to MedPharma Iowa and Tri-Mountain Pure, two medical marijuana operators who wanted to defend the order alongside the government, while allowing them in as amici.

The petitioners' headline theory, that Schedule III cuts taxes on licensed operators, stimulates the industry, and increases marijuana abuse, got no traction. A stay requires a likely win on the merits and irreparable harm, and the court found neither worth a paragraph.

Does this change anything for edibles buyers?

Nothing at the register. Dispensary edibles sell under state law whatever the federal schedule says. The medical-license category has been Schedule III since April 28 and stays there. The practical effect lands on operator costs: 280E relief continues for state medical licensees during the litigation, while hemp-derived products lose federal cover on November 12 and December 11.

We covered the 280E math when the order landed. Section 280E blocks ordinary business deductions for anyone trafficking in Schedule I or II substances, and Schedule III lifts that penalty for the medical-license category.

The April order will be in force when the hemp ban lands on December 11. Hemp products over 0.4mg total THC per container fall back into the marijuana definition that day, and they fall into Schedule I, because the April order covers only licensed medical marijuana and FDA-approved drugs. Same molecule, two schedules, sorted by who holds the license.

What happens next?

Two tracks, neither with a deadline. In the D.C. Circuit, briefing format proposals are due in early October, then merits briefing and argument, with a decision unlikely before 2027. At DEA, Chief Administrative Law Judge Derek Julius still owes a recommended decision on the broader Schedule III proposal covering all marijuana, and no rule requires him to issue it by any date.

The two tracks touch. If the D.C. Circuit eventually holds that the Attorney General cannot reschedule by order, the medical-license category snaps back to Schedule I until the formal rulemaking finishes, and that rulemaking is the one with the judge and no clock. If the court upholds the order, the administrative track becomes the fight over adult-use with the medical channel already settled.

The April order stands. The stay is gone. The people who wanted marijuana kept in Schedule I have told the court, in writing, what it would cost them. The court read it and moved on.